N/A
N=140
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
Plaque Psoriasis Patients
Bottom Line
View on ClinicalTrials.gov: NCT01557283 ↗Enrolled (actual)
140
Serious AEs
5.1%
Results posted
Jun 2014
Primary outcome: Primary: Number of Weeks of Etanercept Treatment — 48.1874 weeks
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Enbrel treatment (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Jun 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Weeks of Etanercept Treatment |
48.1874 | — |
| SECONDARY Number of Weeks of Off-Treatment |
5.5348 | — |
| SECONDARY Psoriasis Area and Severity Index (PASI) Score |
10.913; 6.680; 6.395; 5.571; 5.504; 5.468 | — |
| SECONDARY Percentage of Body Surface Area (BSA) Affected by Psoriasis |
14.189; 8.016; 7.579; 5.361; 5.706; 10.221 | — |
| SECONDARY Number of Participants With Reasons for Treatmant Discontinuation |
19; 7; 1; 1; 1; 1 | — |
Summary
With the new reimbursement criteria, we want:
To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year.
To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment
Eligibility Criteria
Inclusion Criteria
- Patient restarts or is starting treatment with Enbrel for his/her psoriasis in alignment with reimbursement criteria
- Patients ≥18 year
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria
N/A
Data sourced from ClinicalTrials.gov (NCT01557283). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.